173 related articles for article (PubMed ID: 12164939)
1. A highly decreased binding of cyclic adenosine monophosphate to protein kinase A in erythrocyte membranes is specific for active psoriasis.
Schopf RE; Langendorf Y; Benz RE; Färber L; Benes P
J Invest Dermatol; 2002 Jul; 119(1):160-5. PubMed ID: 12164939
[TBL] [Abstract][Full Text] [Related]
2. A cAMP binding abnormality in psoriasis.
Raynaud F; Gerbaud P; Enjolras O; Gorin I; Donnadieu M; Anderson WB; Evain-Brion D
Lancet; 1989 May; 1(8648):1153-6. PubMed ID: 2566733
[TBL] [Abstract][Full Text] [Related]
3. Rapid effect of treatment of psoriatic erythrocytes with the synthetic retinoid acitretin to increase 8-azido cyclic AMP binding to the RI regulatory subunit.
Raynaud F; Gerbaud P; Bouloc A; Gorin I; Anderson WB; Evain-Brion D
J Invest Dermatol; 1993 Jan; 100(1):77-81. PubMed ID: 8380830
[TBL] [Abstract][Full Text] [Related]
4. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.
Mahrle G; Schulze HJ; Färber L; Weidinger G; Steigleder GK
J Am Acad Dermatol; 1995 Jan; 32(1):78-88. PubMed ID: 7822521
[TBL] [Abstract][Full Text] [Related]
5. Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A.
Schopf RE; Hultsch T; Lotz J; Bräutigam M
J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):234-9. PubMed ID: 9883435
[TBL] [Abstract][Full Text] [Related]
6. Topical psoriasis therapy.
Federman DG; Froelich CW; Kirsner RS
Am Fam Physician; 1999 Feb; 59(4):957-62, 964. PubMed ID: 10068717
[TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro influence of etretinate on erythrocyte membrane fluidity.
Górnicki A; Gutsze A
Eur J Pharmacol; 2001 Jul; 423(2-3):127-34. PubMed ID: 11448476
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial of the efficacy and safety of oral etretinate with calcipotriol cream compared with etretinate alone in moderate-severe psoriasis.
Giannetti A; Coppini M; Bertazzoni MG; Califano A; Altieri E; Pazzaglia A; Lega M; Lombardo M; Pelfini C; Veller Fornasa C; Rabbiosi G; Cespa M
J Eur Acad Dermatol Venereol; 1999 Sep; 13(2):91-5. PubMed ID: 10568486
[TBL] [Abstract][Full Text] [Related]
9. Treatment of psoriasis with retinoids: present status.
Orfanos CE
Cutis; 1999 Nov; 64(5):347-53. PubMed ID: 10582161
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of psoriasis vulgaris treatments: analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010.
Akasaka E; Mabuchi T; Manabe Y; Yahagi E; Yamada-Hiruma A; Yamaoka H; Kojima T; Kato M; Ikoma N; Ozawa A; Haruki Y
J Dermatol; 2013 Apr; 40(4):238-43. PubMed ID: 23330814
[TBL] [Abstract][Full Text] [Related]
11. Deficiency of cyclic AMP-dependent protein kinases in human psoriasis.
Brion DE; Raynaud F; Plet A; Laurent P; Leduc B; Anderson W
Proc Natl Acad Sci U S A; 1986 Jul; 83(14):5272-6. PubMed ID: 3014540
[TBL] [Abstract][Full Text] [Related]
12. 1,N6-Etheno-2-aza-adenosine 3', 5'-cyclic phosphate: human erythrocyte membrane binding and activation of membrane protein kinase.
Tsukamoto T; Sonenberg M
J Cyclic Nucleotide Res; 1979; 5(2):153-9. PubMed ID: 221554
[TBL] [Abstract][Full Text] [Related]
13. Retinoylation of the type II cAMP-binding regulatory subunit of cAMP-dependent protein kinase is increased in psoriatic human fibroblasts.
Tournier S; Raynaud F; Gerbaud P; Lohmann SM; Anderson WB; Evain-Brion D
J Cell Physiol; 1996 May; 167(2):196-203. PubMed ID: 8613459
[TBL] [Abstract][Full Text] [Related]
14. Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists.
Katz HI
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 2):S62-8. PubMed ID: 9344188
[TBL] [Abstract][Full Text] [Related]
15. Post-translational abnormality of the type II cyclic AMP-dependent protein kinase in psoriasis: modulation by retinoic acid.
Tournier S; Gerbaud P; Anderson WB; Lohmann SM; Evain-Brion D; Raynaud F
J Cell Biochem; 1995 Apr; 57(4):647-54. PubMed ID: 7615649
[TBL] [Abstract][Full Text] [Related]
16. A study of adenosine 3'-5' cyclic monophosphate binding sites of human erythrocyte membranes using 8-azidoadenosine 3'-5' cyclic monophosphate, a photoaffinity probe.
Owens JR; Haley BE
J Supramol Struct; 1976; 5(1):91-102. PubMed ID: 186666
[TBL] [Abstract][Full Text] [Related]
17. An update on topical therapies for mild-moderate psoriasis.
van de Kerkhof PC
Dermatol Clin; 2015 Jan; 33(1):73-7. PubMed ID: 25412784
[TBL] [Abstract][Full Text] [Related]
18. Effect of psoriasis treatment on plasma concentrations of metalloproteinase-1 and tissue inhibitor of metalloproteinases-1.
Flisiak I; Myśliwiec H; Chodynicka B
J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):418-21. PubMed ID: 15987285
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports).
Kokelj F; Plozzer C; Torsello P; Trevisan G
J Eur Acad Dermatol Venereol; 1998 Sep; 11(2):177-9. PubMed ID: 9784049
[TBL] [Abstract][Full Text] [Related]
20. Treatment of psoriasis in the Nordic countries: a questionnaire survey from 5739 members of the psoriasis associations data from the Nordic Quality of Life Study.
Zachariae H; Zachariae R; Blomqvist K; Davidsson S; Molin L; Mørk C; Sigurgeirsson B
Acta Derm Venereol; 2001 May; 81(2):116-21. PubMed ID: 11501648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
